From: The prognostic significance of tumour-stroma ratio in endometrial carcinoma
 | Overall survival | Disease-free survival | ||
---|---|---|---|---|
Factor | HR (95Â % CI) | P | HR (95Â % CI) | P |
LogTSR (continuous) | 1.75 (1.04–2.94) | 0.034 | 1.61 (0.98–2.64) | 0.058 |
TSR ( ≥1.30 vs. <1.30) | 2.51 (1.22–5.14) | 0.012 | 2.18 (1.15–4.16) | 0.017 |
Age (continuous) | 1.07 (1.05–1.09) | <0.001 | 1.06 (1.05–1.08) | <0.001 |
Stage (FIGO 2009) | Â | Â | Â | Â |
 I | Referent | Referent | Referent | Referent |
 II | 1.83 (1.00–3.36) | 0.051 | 1.69 (0.94–3.01) | 0.078 |
 III | 3.21 (2.10–4.90) | <0.001 | 2.93 (1.96–4.39) | <0.001 |
 IV | 11.44 (6.72–19.32) | <0.001 | 9.15 (5.52–15.15) | <0.001 |
Grade | Â | Â | Â | Â |
 1 | Referent | Referent | Referent | Referent |
 2 | 1.61 (0.95–2.75) | 0.080 | 1.53 (0.93–2.49) | 0.092 |
 3 | 3.49 (2.22–5.49) | <0.001 | 2.95 (1.94–4.48) | <0.001 |
Lymphovascular invasion (yes vs. no) | 3.00 (2.04–4.42) | <0.001 | 2.81 (1.95–4.04) | <0.001 |